Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection
IntroductionCatheter-related blood stream infection (CRBSI) is one of the most relevant complications associated to the use of intravascular catheters. In this context, chlorhexidine gluconate (CHG) releasing dressings have been developed to reduce the catheter colonization rate and the risk of infe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1335364/full |
| _version_ | 1797362294761455616 |
|---|---|
| author | Emili Masferrer Laura Riera-Rodríguez Víctor Farré-Alins Sandra Vilà de Muga Francisco-Javier Arroyo-Muñoz María-Dolores González-Caro |
| author_facet | Emili Masferrer Laura Riera-Rodríguez Víctor Farré-Alins Sandra Vilà de Muga Francisco-Javier Arroyo-Muñoz María-Dolores González-Caro |
| author_sort | Emili Masferrer |
| collection | DOAJ |
| description | IntroductionCatheter-related blood stream infection (CRBSI) is one of the most relevant complications associated to the use of intravascular catheters. In this context, chlorhexidine gluconate (CHG) releasing dressings have been developed to reduce the catheter colonization rate and the risk of infection. The aim of this study is to analyze the release rate of CHG and the antimicrobial activity of a novel CHG-releasing dressing, Oper film® protect CHG, and to compare these parameters to those of the dressing Tegaderm™ CHG in healthy volunteers.MethodsThe study was performed in a cohort of 25 healthy volunteers. Two commercially available chlorhexidine-containing dressings were evaluated and compared in this study, Oper film® protect CHG and Tegaderm™ CHG. The release of CHG and the antimicrobial capacity was determined for one week.ResultsHPLC analysis revealed that both dressings have an equivalent CHG release to the skin 2 days (Oper film® protect CHG, 321 μg/cm2; Tegaderm™ CHG, 279 μg/cm2) and 7 days (Oper film® protect CHG, 456 μg/cm2; Tegaderm™ CHG, 381 μg/cm2) after the placement of the products in the non-disinfected back of the subjects. On the other hand, Oper film® protect CHG and Tegaderm™ CHG similarly reduced colony forming units (CFU) in cultures obtained from the skin under the CHG-containing hydrogel compared to control cultures at both 2 days (control, 3.34 log10 cfu/cm2; Oper film® protect CHG, 0.64 log10 cfu/cm2; Tegaderm™ CHG, 0.7 log10 cfu/cm2) and 7 days (control, 3.95 log10 cfu/cm2; Oper film® protect CHG, 0.11 log10 cfu/cm2; Tegaderm™ CHG, 1 log10 cfu/cm2).DiscussionData confirm that the recent commercially available dressing Oper film® protect CHG maintains the release of CHG and the antimicrobial activity during at least 7 days, and possesses equivalent drug release and antimicrobial action to Tegaderm™ CHG. |
| first_indexed | 2024-03-08T16:06:13Z |
| format | Article |
| id | doaj.art-281c0316cbac40dd93a98efab98c0e1b |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-08T16:06:13Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-281c0316cbac40dd93a98efab98c0e1b2024-01-08T05:42:09ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-01-011010.3389/fmed.2023.13353641335364Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infectionEmili Masferrer0Laura Riera-Rodríguez1Víctor Farré-Alins2Sandra Vilà de Muga3Francisco-Javier Arroyo-Muñoz4María-Dolores González-Caro5Department of Dermatology, Hospital Universitari Mútua Terrassa, Terrassa, SpainDepartment of Dermatology, Hospital Universitari Mútua Terrassa, Terrassa, SpainIberhospitex, S.A., Barcelona, SpainIberhospitex, S.A., Barcelona, SpainIntensive Care Unit, Hospital Universitario Virgen Macarena, Sevilla, SpainIntensive Care Unit, Hospital Universitario Virgen Macarena, Sevilla, SpainIntroductionCatheter-related blood stream infection (CRBSI) is one of the most relevant complications associated to the use of intravascular catheters. In this context, chlorhexidine gluconate (CHG) releasing dressings have been developed to reduce the catheter colonization rate and the risk of infection. The aim of this study is to analyze the release rate of CHG and the antimicrobial activity of a novel CHG-releasing dressing, Oper film® protect CHG, and to compare these parameters to those of the dressing Tegaderm™ CHG in healthy volunteers.MethodsThe study was performed in a cohort of 25 healthy volunteers. Two commercially available chlorhexidine-containing dressings were evaluated and compared in this study, Oper film® protect CHG and Tegaderm™ CHG. The release of CHG and the antimicrobial capacity was determined for one week.ResultsHPLC analysis revealed that both dressings have an equivalent CHG release to the skin 2 days (Oper film® protect CHG, 321 μg/cm2; Tegaderm™ CHG, 279 μg/cm2) and 7 days (Oper film® protect CHG, 456 μg/cm2; Tegaderm™ CHG, 381 μg/cm2) after the placement of the products in the non-disinfected back of the subjects. On the other hand, Oper film® protect CHG and Tegaderm™ CHG similarly reduced colony forming units (CFU) in cultures obtained from the skin under the CHG-containing hydrogel compared to control cultures at both 2 days (control, 3.34 log10 cfu/cm2; Oper film® protect CHG, 0.64 log10 cfu/cm2; Tegaderm™ CHG, 0.7 log10 cfu/cm2) and 7 days (control, 3.95 log10 cfu/cm2; Oper film® protect CHG, 0.11 log10 cfu/cm2; Tegaderm™ CHG, 1 log10 cfu/cm2).DiscussionData confirm that the recent commercially available dressing Oper film® protect CHG maintains the release of CHG and the antimicrobial activity during at least 7 days, and possesses equivalent drug release and antimicrobial action to Tegaderm™ CHG.https://www.frontiersin.org/articles/10.3389/fmed.2023.1335364/fulldressingschlorhexidinehydrogelcatheter-related bloodstream infectionantimicrobial activity |
| spellingShingle | Emili Masferrer Laura Riera-Rodríguez Víctor Farré-Alins Sandra Vilà de Muga Francisco-Javier Arroyo-Muñoz María-Dolores González-Caro Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection Frontiers in Medicine dressings chlorhexidine hydrogel catheter-related bloodstream infection antimicrobial activity |
| title | Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection |
| title_full | Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection |
| title_fullStr | Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection |
| title_full_unstemmed | Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection |
| title_short | Randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel-containing chlorhexidine dressing to prevent catheter-related bloodstream infection |
| title_sort | randomized controlled trial on healthy volunteers of pharmacokinetic and antimicrobial activity of a novel hydrogel containing chlorhexidine dressing to prevent catheter related bloodstream infection |
| topic | dressings chlorhexidine hydrogel catheter-related bloodstream infection antimicrobial activity |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1335364/full |
| work_keys_str_mv | AT emilimasferrer randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection AT laurarierarodriguez randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection AT victorfarrealins randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection AT sandravilademuga randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection AT franciscojavierarroyomunoz randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection AT mariadoloresgonzalezcaro randomizedcontrolledtrialonhealthyvolunteersofpharmacokineticandantimicrobialactivityofanovelhydrogelcontainingchlorhexidinedressingtopreventcatheterrelatedbloodstreaminfection |